Group 1 - The company is holding its 2024 Annual General Meeting on May 30, 2025 [1] - The original notice for the AGM omitted a resolution regarding the change of the company's business scope and the amendment of relevant articles in the Articles of Association, which has now been added as a special resolution [2] - The original notice of the AGM remains unchanged aside from the added resolution [3] Group 2 - The AGM will take place at 14:00 on May 30, 2025, in the company's conference room [5] - Online voting will be conducted through the Shanghai Stock Exchange's shareholder meeting online voting system, available from 9:15 to 15:00 on the day of the meeting [5] - The record date for shareholders to participate in the AGM remains unchanged [6] Group 3 - Non-voting matters include listening to the independent directors' 2024 annual work report [7]

证券代码：600064 证券简称：南京高科 公告编号：临 2025-016 号 南京高科股份有限公司 关于2024年年度股东会补充公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 股东会有关情况 1. 原股东会的类型和届次： 2024年年度股东会 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | Ａ股 | 600064 | 南京高科 | 2025/5/26 | 二、 更正补充事项涉及的具体内容和原因 南京高科股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日披露了《南 京高科股份有限公司关于召开 2024 年年度股东会的通知》（公告编号：临 2025-013 号），经核查，本次股东会通知遗漏了《关于变更公司经营范围暨修订 〈公司章程〉相关条款的议案》，该议案已经公司 2024 年 11 月 1 日第十一届董 事会第四次会议审议通过，具体详见公司临 2024-040 号公告。现将本次股东会 审议议案在原议案基础上增加《关于变更公司经营范 ...

Group 1 - The company will hold a 2024 annual performance briefing on May 15, 2025, from 15:00 to 16:30 [3][6] - The briefing will be conducted via the "Nanjing Gaoke Investor Relations" mini-program, combining live video and text interaction [3][6] - Investors can submit questions through the mini-program or via email by May 14, 2025, and the company will address common inquiries during the briefing [4][2] Group 2 - Key personnel attending the briefing include the Chairman Xu Yimin, President Lu Yangjun, Independent Director Li Minghui, and other executives [3][6] - The company has previously disclosed its 2024 annual report and summary on various financial news platforms and the Shanghai Stock Exchange website [2]

证券简称：南京高科 证券代码：600064 编号：临 2025-015 号 南京高科股份有限公司 关于召开 2024 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2025 年 5 月 14 日（星期三）前通过"南京高科投资者关系" 小程序或者公司邮箱 600064@600064.com 联系公司进行提问。公司将在业绩说 明会上对投资者普遍关注的问题进行回答。 一、说明会类型 公司已于 2025 年 4 月 23 日在《中国证券报》《上海证券报》《证 券时报》及上海证券交易所网站（www.sse.com.cn）上披露了 2024 年年度报告及摘要。为让广大投资者更全面深入地了解公司经营业绩 和利润分配等具体情况，公司决定以网络互动方式举行 2024 年度业 绩说明会。 二、说明会召开时间和形式 召开时间：2025 年 5 月 15 日（周四）15:00-16:30 召开地址： "南京高科投资者关系"小程序 召开方式：网络视频直播结合文字互动 1 会议召开时间：2025 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company's revenue has decreased due to a contraction in its real estate business, while the net profit attributable to the parent company has increased year-on-year. The company is expected to see continuous improvement in performance due to its strong financing channels [4][5] - The company has provided profit forecasts for 2025-2027, estimating net profits of 2.21 billion, 2.46 billion, and 2.59 billion yuan respectively, with corresponding EPS of 1.3, 1.4, and 1.5 yuan. The current stock price corresponds to PE ratios of 5.7, 5.2, and 4.9 times [4][5] Financial Performance Summary - In 2024, the company achieved operating revenue of 1.98 billion yuan, a year-on-year decrease of 58.16%, while the net profit attributable to the parent company was 1.73 billion yuan, a year-on-year increase of 10.58%. The net profit excluding non-recurring items was 1.62 billion yuan, down 1.54% year-on-year [5][8] - The company's gross margin and net margin for 2024 were 21.88% and 83.09%, respectively, reflecting increases of 9.55 percentage points and 51.72 percentage points year-on-year [5][8] - The company's real estate business saw a significant decline in revenue, with a year-on-year decrease of 84.09% in operating income from real estate development [6][8] Sales and Contract Performance - The company reported a contract sales area of 18,700 square meters in 2024, a year-on-year decrease of 92.66%, and a contract sales amount of 620 million yuan, down 67.59% year-on-year [6] - New construction area and completed area also saw significant declines of 80.78% and 61.93% year-on-year, respectively [6] Financing and Cost Management - The company has maintained smooth financing channels, with an average financing cost of 2.72% in 2024, a decrease of 0.27 percentage points compared to the same period in 2023 [7] - The company has authorized borrowing up to 2 billion yuan from Nanjing Bank, with a loan balance of 300 million yuan as of the end of 2024 [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company's revenue has decreased due to a contraction in its real estate business, while the net profit attributable to shareholders has increased year-on-year. The company is expected to see continuous improvement in performance due to its strong financing channels [4][5] - The company has provided profit forecasts for 2025-2027, estimating net profits of 2.21 billion, 2.46 billion, and 2.59 billion yuan respectively, with corresponding EPS of 1.3, 1.4, and 1.5 yuan. The current stock price corresponds to PE valuations of 5.7, 5.2, and 4.9 times [4][5] Financial Performance Summary - In 2024, the company achieved operating revenue of 1.98 billion yuan, a year-on-year decrease of 58.16%. The net profit attributable to shareholders was 1.73 billion yuan, a year-on-year increase of 10.58%. The net profit excluding non-recurring items was 1.62 billion yuan, a year-on-year decrease of 1.54% [5][8] - The company's operating cash flow was -500 million yuan in 2024, with a gross margin of 21.88% and a net margin of 83.09%, reflecting increases of 9.55 percentage points and 51.72 percentage points year-on-year respectively [5][8] - The real estate business saw a significant decline in revenue, with a year-on-year decrease of 84.09% in operating income from real estate development [5][6] Real Estate Business Overview - The company reported a contract sales area of 18,700 square meters in 2024, a year-on-year decrease of 92.66%, and a contract sales amount of 620 million yuan, a year-on-year decrease of 67.59% [6] - New construction area decreased by 80.78% year-on-year, while the completed area decreased by 61.93% [6] Financing and Cost Management - The company has maintained smooth financing channels, with an average financing cost of 2.72% in 2024, down 0.27 percentage points from the same period in 2023 [7] - The company has authorized borrowing up to 2 billion yuan from Nanjing Bank, with a loan balance of 300 million yuan as of the end of 2024 [7] Financial Metrics and Projections - The company’s financial metrics for 2023A to 2027E show a projected operating revenue of 2.24 billion yuan in 2025E, with a year-on-year growth of 13.6% [8][11] - The projected net profit for 2025E is 2.21 billion yuan, reflecting a year-on-year growth of 28.4% [8][11] - The company’s P/E ratio is projected to decrease from 5.7 in 2025E to 4.9 in 2027E, indicating an improving valuation [8][11]

证券简称：南京高科 证券代码：600064 编号：临 2025-012 号 南京高科股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 拟聘任的会计师事务所名称：天衡会计师事务所（特殊普通合伙） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 （9）财务信息及客户情况：天衡 2024 年度业务收入总额为 52,937.55 万元（人民币，下同），审计业务收入为 46,009.42 万元， 证券业务收入为 15,518.61 万元。天衡 2023 年度上市公司审计客 户数量为 95 家，审计收费总额为 9,271.16 万元，主要行业包括制 造业，电力、热力、燃气及水生产和供应业，科学研究和技术服 务业，信息传输、软件和信息技术服务业，批发和零售业，文化、 体育和娱乐业等，与公司同行业（房地产业）的上市公司审计客 户 1 家。 2、投资者保护能力 2024 年末，天衡计提职业风险基金 2,445.10 万元，购买的职业 保险累计赔偿限额为 10,000. ...

南京高科股份有限公司 未来三年（2025-2027 年）分红规划 为提升公司投资价值，增强投资者回报，维护股东合法权益，根 据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司 监管指引第 3 号——上市公司现金分红》等法律法规及《公司章程》 相关规定，结合公司实际经营情况和发展战略，特制定《南京高科股 份有限公司未来三年（2025-2027 年）分红规划》（以下简称"分红规 划"），具体内容如下： 一、制定分红规划的背景与目的 背景：公司自上市以来，始终坚持稳健经营，积极回馈股东。为 明确投资者预期，建立科学、透明的分红机制，现制定未来三年分红 规划。 目的：平衡股东短期回报与公司长期发展需求，促进股东价值最 大化，提升公司治理水平。 二、现金分红的基本原则 合规性：符合《公司章程》及监管机构对利润分配的要求。 可持续性：以公司盈利能力和现金流为基础，兼顾股东合理回报 与公司发展需求。 公平性：确保全体股东，尤其是中小股东享有平等分红权益。 三、未来三年（2025-2027 年）分红具体规划 分红条件：公司当年实现盈利且累计未分配利润为正；现金流可 1 满足正常经营和战略投资需求；不存在重大投资计划 ...

南京高科股份有限公司 董事会审计委员会2024年度履职情况报告 根据中国证监会《上市公司治理准则》、上海证券交易所《上市 公司自律监管指引第 1 号——规范运作》《股票上市规则》及《公司 章程》和《董事会审计委员会工作细则》等有关规定，公司董事会审 计委员会本着勤勉尽责的原则，认真履行职责，切实维护公司及广大 股东的合法权益。现将 2024 年度审计委员会的履职情况汇报如下： 一、审计委员会基本情况 的报告，同意公司对部分房地产项目计提资产减值准备，同意将此事 项提交公司董事会审议。 3、2024年4月22日，董事会审计委员会审阅了经立信会计师事务 所（特殊普通合伙）出具初步审计意见后的公司2023年度财务报表。 公司审计委员会与公司年审会计师事务所就年报审计以及内部控制 审计工作进行了单独沟通，出具了第二次审阅意见和关于督促会计师 事务所按期提交审计报告的函件。 公司第十届董事会审计委员会由3名董事组成，分别为独立董事 冯巧根先生、独立董事高波先生和董事陆阳俊先生。报告期内，公司 第十届董事会审计委员会任期届满，2024年8月12日，公司董事会审 计委员会完成换届工作。 公司第十一届董事会审计委员会仍由3名 ...

南京高科股份有限公司董事会 根据证监会《上市公司独立董事管理办法》、上海证券交易所《股 票上市规则》《上市公司自律监管指引第 1 号—规范运作》等要求， 独立董事应当每年对任职独立性进行自查，并将自查情况提交董事会。 董事会应当每年对独立董事独立性情况进行评估并出具专项意见。因 此，南京高科股份有限公司（以下简称"公司"）董事会根据法规并 结合独立董事出具的《南京高科股份有限公司独立董事独立性自查报 告》，就公司在任独立董事范从来、李明辉、陈莹及离任独立董事冯 巧根、高波、夏江的独立性情况进行评估并出具如下专项意见： 经核查在任独立董事范从来、李明辉、陈莹及离任独立董事冯巧 根、高波、夏江签署的相关自查文件以及在公司的履职情况，董事会 认为公司全体独立董事均具备胜任独立董事岗位的资格。独立董事及 其配偶、父母、子女、主要社会关系未在公司或公司附属企业任职， 未在公司主要股东及其附属企业任职，未与公司存在重大的持股关系， 与公司及主要股东之间不存在重大业务往来关系或提供财务、法律、 咨询、保荐等服务关系。 因此，公司独立董事均不存在任何妨碍其进行独立客观判断的关 系，不存在影响独立董事独立性的情况，符合《上市公 ...